logo-loader

American Battery Metals appoints CTO to board of directors

Published: 09:53 09 Sep 2020 EDT

American Battery Metals Corporation - American Battery Metals appoints CTO to board of directors
Before joining American Battery Metals, Melsert was the R&D manager for Tesla's Gigafactory battery materials processing group

American Battery Metals Corporation (OTCQB:ABML) said it has appointed its chief technical officer Ryan Melsert to its board of directors.

Melsert joined the company in September 2019 and helped it win the coveted Greentown Labs/BASF Circularity Challenge award for the company's first-of-kind lithium-ion battery recycling process.

He has also assembled a technical team of experts in chemistry, battery engineering, and plant operations and is advancing the company towards the initial construction phase of its first lithium-ion battery recycling facility in Nevada.

WATCH: American Battery Metals breaks ground at its lithium-ion battery recycling pilot plant in Nevada

Before joining American Battery Metals, Melsert was the research & development (R&D) manager for Tesla Inc’s (NASDAQ:TSLA) (FRA:TL0) Gigafactory battery materials processing group.

"I'm grateful for the appointment to the board. Our team is motivated and eager to launch our battery recycling facility, to begin producing high quality, battery-grade metals from end-of-life batteries and manufacturing scrap materials feedstock", Melsert said in a statement.

"Ryan is uniquely qualified to be an officer of our company and to serve on our board as a director. He is one of the world's brightest minds in the battery metals and manufacturing industries, and he is also a strategic business thinker who knows how to turn market challenges into opportunities," added American Battery Metals chief executive Doug Cole.

Contact the author at calum@proactiveinvestors.com

Follow him on Twitter @Cal_Proac

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

15 minutes ago